2019
ENABLE joins the AMR Challenge
January 2019
The AMR Challenge is a way for governments, private industries, and non-governmental organizations worldwide to make formal commitments that further the progress against antimicrobial resistance. ENABLE's commitment has been published here.
ENABLE at the 12th Berlin Conference on Life Sciences
14 - 15 March, 2019
The Novel Antimicrobials and AMR Diagnostics 2019 conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market. ENABLE representatives will join to the conference as speakers.
Information about ENABLE no-cost extension
ENABLE is at an advanced stage in seeking approval from IMI for a 1 year no-cost extension. The request is for an extension in time (End Date 31/01/2021) and also in scope. The broadening of ENABLE scope will allow us to consider programmes with direct acting antibacterial compounds targeting the Enterobacteriaceae, P. aeruginosa, and/or A. baumannii, and to consider programmes submitted by any individual EFPIA member (not only those currently in ENABLE).
Expressions of Interest may be submitted to ENABLE by academic groups, SMEs, or individual EFPIA members up until 26. August 2019. At this stage we do not know for certain whether a 1 year no cost extension will be approved but the initial informal feedback from IMI has been positive. Although formalization through an amendment will take some time, IMI has given the green light to plan for the extension. We therefore encourage any eligible groups or organizations to begin preparing their submission to ENABLE for no later than 26. August 2019.
6th ENABLE Annual Meeting held in Warsaw
24 - 25 September 2019
From 24-25 September 2019, this year’s ENABLE Annual Meeting took place in Warsaw, Poland. The meeting achieved an all-time high attendance record with over 90 attendees. The public-private partnership initiative with partners from EFPIA companies, SMEs, academia and independent experts met to discuss the progress of the quickly developing programmes. As ENABLE is coming to an end in 2021 including the one-year extension, the meeting presented the last opportunity for new teams to enter the initiative.
At this time, the ENABLE project has received 110 Expressions of Interest. Around half of these applications were able to present in front of the expert body of ENABLE, the Portfolio Management Committee. Again, around half of the Expressions of Interest were approved and received funding from ENABLE resources. Currently, the engine progresses eight programmes.
Article on ENABLE published: Scientists aim for new weapons in fight against superbugs
14 October 2019
"New weapons are needed to fight drug-resistant bacteria, one of the biggest threats to global health. By working on new antibiotics or finding ways to revive existing ones in our medical arsenal, scientists aim to avoid a return to a world where even everyday infections may mean death." Anders Karlén and Diarmaid Hughes gave an interview to the HORIZON EU Research & Innovation Magazine. You can read the article here.
Two ENABLE Press Releases published
18 November 2019
A Press Release on the candidate selection of Mutabilis and the entry into Phase I by Juvabis. Both press releases can be downloaded here.
